Investors & Media Press Releases Investor Relations Overview Corporate Governance Press Releases & Statements Events & Presentations SEC Filings Annuals and Proxies Investor FAQs Financials & Filings Stock Information Analyst Coverage Email Alerts Subscription Notice of Pendency of Settlement of Action Press Releases Items Per Page 102550 Year None20242023202220212020201920182017 Date Title View Toggle Summary April 17, 2024 Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease Toggle Summary April 11, 2024 Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 Toggle Summary March 26, 2024 Sage Therapeutics Announces Dr. Steve Paul to Retire from Board of Directors Sage Therapeutics Announces Dr. Steve Paul to Retire from Board of Directors Toggle Summary February 28, 2024 Sage Therapeutics to Present at Upcoming March Investor Conferences Sage Therapeutics to Present at Upcoming March Investor Conferences Toggle Summary February 14, 2024 Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary January 31, 2024 Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Toggle Summary January 31, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Toggle Summary January 8, 2024 Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Toggle Summary January 8, 2024 Sage Therapeutics Announces Changes to Board of Directors Sage Therapeutics Announces Changes to Board of Directors Toggle Summary January 2, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
Press Releases Items Per Page 102550 Year None20242023202220212020201920182017 Date Title View Toggle Summary April 17, 2024 Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease Toggle Summary April 11, 2024 Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 Toggle Summary March 26, 2024 Sage Therapeutics Announces Dr. Steve Paul to Retire from Board of Directors Sage Therapeutics Announces Dr. Steve Paul to Retire from Board of Directors Toggle Summary February 28, 2024 Sage Therapeutics to Present at Upcoming March Investor Conferences Sage Therapeutics to Present at Upcoming March Investor Conferences Toggle Summary February 14, 2024 Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary January 31, 2024 Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Toggle Summary January 31, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Toggle Summary January 8, 2024 Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Toggle Summary January 8, 2024 Sage Therapeutics Announces Changes to Board of Directors Sage Therapeutics Announces Changes to Board of Directors Toggle Summary January 2, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
